Stealth BioTherapeutics MMPOWER-2 and REPOWER Study Update

Print Friendly, PDF & Email

Stealth BioTherapeutics patient/community update on MMPOWER-2 and RePOWER Primary Mitochondrial Myopathy clinical trials

Stealth’s CEO Reenie McCarthy and Chief Clinical Development Officer Jim Carr shares updates on Stealth’s second clinical trial for mitochondrial myopathy, the MMPOWER-2 study.

Join us for this free webinar to learn more about:

  • Safety and tolerability data of elamipretide (previously known as Bendavia) from the MMPOWER-2 study
  • Tests and assessments used to measure efficacy of elamipretide in the MMPOWER-2 trial
  • Endpoints and outcomes from the MMPOWER-2 trial for people ages 16-65 with genetically-confirmed mitochondrial myopathy
  • Future Stealth BT studies evaluating elamipretide and mitochondrial myopathy
  • All are welcome and encouraged to listen to this live presentation. An opportunity to submit questions online will be provided during the live webinar.

 

 

Date: 08/11/2017
Speaker: Reenie McCarthy & Jim Carr
PDF: Click Here

Related Articles

Stealth BioTherapeutics MMPOWER Update
Date: 12/06/2016
Speaker: Reenie McCarthy
PDF: Click Here
Stealth BioTherapeutics MMPOWER-2 and REPOWER Study Update
Date: 08/11/2017
Speaker: Reenie McCarthy & Jim Carr
PDF: Click Here
Drug Trial Begins Targeting Mitochondrial Diseases
Date: 07/15/2008
Speaker: Dr. Guy Miller